Literature DB >> 28684826

Aggressive denosumab-related jaw necrosis - a case series.

M Badr1, E Kyriakidou2, S Atkins3, S Harrison4.   

Abstract

Medication related osteonecrosis of the jaw is becoming a repeatedly seen complication in cancer patients. Stage 0 of the disease is more likely to be seen by the patients' general dental practitioners. We are presenting four cases of MRONJ related to denosumab treatment showing increasingly aggressive pictures of the disease. Nevertheless, we also present a good response to a drug holiday arranged by the patients' treating oncologists.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28684826     DOI： 10.1038/sj.bdj.2017.573

Source DB:  PubMed          Journal:  Br Dent J        ISSN： 0007-0610            Impact factor:   1.626


  8 in total

Review 1.  Skeletal complications in cancer patients with bone metastases.

Authors:  Shunsuke Tsuzuki; Sun Hee Park; Matthew R Eber; Christopher M Peters; Yusuke Shiozawa
Journal:  Int J Urol       Date:  2016-08-03       Impact factor: 3.369

Review 2.  Epidemiology and pathogenesis of osteonecrosis of the jaw.

Authors:  Ian R Reid; Jillian Cornish
Journal:  Nat Rev Rheumatol       Date:  2011-11-29       Impact factor: 20.543

3.  Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.

Authors:  Rebecca Anne Miksad; Kuan-Chi Lai; Thomas Benton Dodson; Sook-Bin Woo; Nathaniel Simon Treister; Omosalewa Akinyemi; Marian Bihrle; Guy Maytal; Meredith August; G Scott Gazelle; J Shannon Swan
Journal:  Oncologist       Date:  2011-01-06

4.  The relationship of denosumab pharmacology and osteonecrosis of the jaws.

Authors:  John Malan; Kyle Ettinger; Erich Naumann; O Ross Beirne
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-12

Review 5.  Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.

Authors:  Toru Hiraga
Journal:  Expert Opin Investig Drugs       Date:  2016-02-06       Impact factor: 6.206

6.  Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.

Authors:  Wei-Xiang Qi; Li-Na Tang; Ai-Na He; Yang Yao; Zan Shen
Journal:  Int J Clin Oncol       Date:  2013-04-20       Impact factor: 3.402

7.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976

8.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136
  8 in total
  2 in total

1.  Oral surgery: The drug holiday.

Authors:  D Shiels; A Goodall
Journal:  Br Dent J       Date:  2017-10-13       Impact factor: 1.626

2.  Erratum.

Authors: 
Journal:  Br Dent J       Date:  2017-08-25       Impact factor: 1.626
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.